ProImmune Expands Global Headquarters to Drive Next-Generation Immunology and Life Science Innovation
ProImmune Ltd, a global leader in life science reagents and immunology services, has officially opened its new global headquarters at Oasis Park in Oxford. The move marks a major milestone in the company’s growth journey, enabling a significant expansion of its research, development, and operational capabilities to better serve its worldwide customer base.
The new 18,000 square foot headquarters represents a substantial investment in cutting-edge laboratory facilities and office spaces, designed to accelerate innovation and expand capacity across ProImmune’s rapidly growing portfolio. The company’s relocation to Oasis Park places it at the heart of one of the world’s leading bioscience and innovation ecosystems, providing access to a vibrant community of pioneering life science organizations and research institutions.
Oasis Park, encompassing a total of 70,000 square feet of premium scientific and commercial space, is already home to several innovative companies that form part of Oxford’s thriving biotech corridor. ProImmune’s new facility is one of the most advanced within the complex, tailored specifically to support its expanding research programs and the continued development of technologies that are shaping the future of immunology and therapeutic discovery.
Founded with a mission to advance the understanding of immune responses and support the development of safer, more effective therapeutics, ProImmune has become a trusted partner for leading pharmaceutical, biotechnology, and academic institutions around the world. Its specialized reagents and analytical services have been integral in driving innovation across vaccine development, immunogenicity assessment, and antibody engineering.
The new headquarters will allow ProImmune to further enhance the scope and efficiency of its flagship platforms, including the REVEAL® Immunogenicity System and the Ankyron® target binding reagent platform. Both technologies are central to the company’s mission of providing high-precision solutions that empower researchers to better characterize and predict immune responses.
The REVEAL® Immunogenicity System, one of ProImmune’s cornerstone offerings, provides comprehensive insight into how the immune system responds to therapeutic candidates and vaccines. By enabling the detailed analysis of antigen presentation and T-cell activation, REVEAL® helps researchers identify potential immunogenicity risks early in the drug development process. This capability is essential for improving the safety and efficacy of biotherapeutics, vaccines, and gene therapy products. The expanded laboratory infrastructure at Oasis Park will allow ProImmune to meet increasing demand for these services from clients worldwide, while also accelerating new assay development.
Alongside REVEAL®, the company’s proprietary Ankyron® technology continues to gain attention as a transformative platform for molecular recognition. Ankyrons—engineered recombinant ankyrin repeat proteins—offer a powerful, reproducible, and cost-effective alternative to traditional antibodies. Unlike antibodies, which can be time-consuming and costly to generate, Ankyrons can be designed rapidly to target specific molecules with exceptional sensitivity and specificity. This innovation addresses a long-standing challenge in the field of antibody research, providing scientists with robust tools for target validation, biomarker detection, and therapeutic development.
“Establishing our new global headquarters at Oasis Park reflects ProImmune’s ongoing commitment to scientific excellence and innovation in immunology,” said Dr. Nikolai Schwabe, Chief Executive Officer of ProImmune. “This investment gives us the space, flexibility, and infrastructure to scale our operations and to continue delivering world-class products and services. Most importantly, it strengthens our ability to help our partners develop safer and more effective therapies that make a real difference to patients worldwide.”
Dr. Schwabe emphasized that the company’s expansion is not just a logistical upgrade, but a strategic investment in the future of immunology research. The new facility has been designed to promote collaboration and adaptability, featuring modular laboratory spaces that can be rapidly reconfigured as projects evolve. This flexibility enables ProImmune’s scientists to work more efficiently on complex projects spanning immunogenicity testing, biomarker discovery, and therapeutic protein design.
The location at Oasis Park also reinforces ProImmune’s connection to Oxford’s globally recognized life science cluster. Home to some of the most influential academic and commercial research institutions in the world, Oxford has long been a hub for biomedical innovation. ProImmune’s proximity to leading universities, research hospitals, and biotechnology firms fosters opportunities for collaboration, recruitment, and joint scientific initiatives that advance the frontiers of immunology and one-health biology.
The company’s growth reflects a broader trend within the life sciences sector, as organizations invest in expanded facilities to meet rising global demand for biologics, vaccines, and immune-based therapies. With advances in immunology driving progress in areas such as oncology, infectious disease, and autoimmune disorders, ProImmune’s expertise and technologies are increasingly in demand among pharmaceutical and biotechnology innovators seeking deeper insights into immune mechanisms.
In addition to scientific advancement, the new headquarters underscores ProImmune’s commitment to sustainability and workforce wellbeing. The facility incorporates energy-efficient systems, optimized air handling, and sustainable materials, ensuring compliance with modern environmental standards. The expanded workspace also provides enhanced amenities for staff, including collaborative meeting areas, dedicated research zones, and flexible office layouts that support both focus and teamwork.
“This expansion is as much about our people as it is about our science,” added Dr. Schwabe. “Our success is built on the expertise and dedication of our teams. The new headquarters provides an inspiring environment that empowers them to continue pushing the boundaries of immunological research.”
As ProImmune embarks on this next chapter, the company remains focused on its core mission: advancing immunology to improve global health outcomes. The opening of the new global headquarters marks a defining moment in that mission—one that positions the company to accelerate discovery, strengthen partnerships, and continue its leadership at the cutting edge of life science innovation.
